Oncotarget

Research Papers:

Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma

Sebastian Frees _, Ines Breuksch, Tobias Haber, Heide-Katharina Bauer, Claudia Chavez-Munoz, Peter Raven, Igor Moskalev, Ninadh D´Costa, Zheng Tan, Mads Daugaard, Joachim W. Thüroff, Axel Haferkamp, Dirk Prawitt, Alan So and Walburgis Brenner

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:15766-15779. https://doi.org/10.18632/oncotarget.24607

Metrics: PDF 840 views  |   HTML 1645 views  |   ?  


Abstract

Sebastian Frees1,2,*, Ines Breuksch3,*, Tobias Haber2, Heide-Katharina Bauer3, Claudia Chavez-Munoz1, Peter Raven1, Igor Moskalev1, Ninadh D´Costa1, Zheng Tan1, Mads Daugaard1, Joachim W. Thüroff2,4, Axel Haferkamp2, Dirk Prawitt5, Alan So1 and Walburgis Brenner2,3

1Department of Urologic Sciences, University of British Columbia, Vancouver Prostate Centre, British Columbia, Canada

2Department of Urology, Johannes Gutenberg University Medical Center, Mainz, Germany

3Department of Gynecology, Johannes Gutenberg University Medical Center, Mainz, Germany

4Current address: Department of Urology, University Clinic Mannheim, Mannheim, Germany

5Department of Pediatrics, Johannes Gutenberg University Medical Center, Mainz, Germany

*These authors contributed equally to this work

Correspondence to:

Sebastian Frees, email: sebastian.frees@unimedizin-mainz.de

Keywords: renal cell carcinoma; calcium-sensing receptor; bone metastases, metastasis; kidney cancer

Received: December 21, 2017     Accepted: February 25, 2018     Epub: March 02, 2018     Published: March 20, 2018

ABSTRACT

Bone metastasis is an important prognostic factor in renal cell carcinoma (RCC). The calcium-sensing receptor (CaSR) has been associated with bone metastasis in several different malignancies. We analyzed the impact of CaSR in bone metastasis in RCC in vitro and in vivo. The RCC cell line 786-O was stably transfected with the CaSR gene and treated with calcium alone or in combination with the CaSR antagonist NPS2143. Afterwards migration, adhesion, proliferation and prominent signaling molecules were analyzed. Calcium treated CaSR-transfected 768-O cells showed an increased adhesion to endothelial cells and the extracellular matrix components fibronectin and collagen I, but not to collagen IV. The chemotactic cell migration and proliferation was also induced by calcium. The activity of SHC, AKT, ERK, P90RSK and JNK were enhanced after calcium treatment of CaSR-transfected cells. These effects were abolished by NPS2143. Development of bone metastasis was evaluated in vivo in a mouse model. Intracardiac injection of CaSR-transfected 768-O cells showed an increased rate of bone metastasis. The results indicate CaSR as an important component in the mechanism of bone metastasis in RCC. Therefore, targeting CaSR might be beneficial in patients with bone metastatic RCC with a high CaSR expression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24607